PFE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Pfizer Inc (PFE) is not a strong buy at the moment for a beginner investor with a long-term focus. The stock lacks immediate positive catalysts, has weak financial performance, and no strong trading signals. While there are some positive developments in its pipeline, the overall sentiment and technical indicators suggest holding off on investment for now.
The MACD is negatively expanding (-0.0928), RSI is neutral at 30.273, and moving averages are converging, indicating no clear bullish or bearish trend. The stock is trading near its support level (S1: 26.57), with resistance at 27.13, showing limited upward momentum.
Pfizer's weight management treatment Xianweiying is now available for pre-order in China, and the company presented advancements in cancer treatments at the ASCO meeting. Analysts like Argus and Guggenheim have expressed confidence in the company's long-term growth potential.
Weak Q4 financials with a significant drop in revenue (-1.16% YoY), net income (-501.95% YoY), and EPS (-514.29% YoY). The CDC's blocking of a COVID-19 vaccine study raises concerns about vaccine-related controversies. Competitors like AbbVie and Merck are showing stronger financial and strategic positions.
In 2025/Q4, Pfizer's revenue dropped to $17.56 billion (-1.16% YoY), net income fell significantly to -$1.65 billion (-501.95% YoY), and EPS dropped to -$0.29 (-514.29% YoY). Gross margin increased to 64.15% (+6.00% YoY), but overall financial performance remains weak.
Analysts are mixed on Pfizer. Recent ratings include UBS raising the price target to $27 (Neutral), Morgan Stanley raising it to $28 (Equal Weight), and RBC Capital maintaining an Underperform rating with a $25 target. Positive ratings from Guggenheim ($36 target) and Argus ($35 target) reflect confidence in long-term growth but do not address immediate challenges.
